Your browser doesn't support javascript.
loading
Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer
Shimizu, T; Nakagawa, Y; Takahashi, N; Hashimoto, S.
Affiliation
  • Shimizu, T; Nihon University School of Medicine. Department of Internal Medicine. Division of Respiratory Medicine. Tokyo. Japan
  • Nakagawa, Y; Nihon University School of Medicine. Department of Internal Medicine. Division of Respiratory Medicine. Tokyo. Japan
  • Takahashi, N; Nihon University School of Medicine. Department of Internal Medicine. Division of Respiratory Medicine. Tokyo. Japan
  • Hashimoto, S; Nihon University School of Medicine. Department of Internal Medicine. Division of Respiratory Medicine. Tokyo. Japan
Clin. transl. oncol. (Print) ; 18(1): 107-112, ene. 2016. tab, ilus, graf
Article in English | IBECS | ID: ibc-148059
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
Background. Thymidylate synthase (TYMS) expression in lung cancer tissue affects the therapeutic efficacy of pemetrexed (PMT). TYMS protein expression is primarily assessed using immunohistochemistry (IHC), but this method is not suitable for accurate quantitative analysis. It is not known whether the analysis of TYMS gene copy number using fluorescence in situ hybridization (FISH) is a useful method for assessment of TYMS expression. Patients and methods. The participants were patients with chemo-naïve advanced NSCLC treated with PMT plus carboplatin (CBDCA) in prospective clinical phase II study. TYMS expression was evaluated in 40 patients by gene copy number and protein expression using FISH and IHC. Therapeutic efficacy was evaluated by investigating the response rate (RR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Results. TYMS gene amplification was detected in 8 patients (32 %) among 25 patients who could be evaluated for TYMS gene copy number. There were no patients with complete or partial response in the TYMS amplified group. RR and DCR were lower in the TYMS amplified group compared with the TYMS unamplified group (0 versus 35.3 %, p = 0.0539, 62.5 versus 94.1 %, p = 0.0443). PFS and OS were reduced in the TYMS amplified group. The analysis of TYMS gene copy number had higher sensitivity and specificity compared with TYMS protein expression (76.2 versus 50.0 %, 75.0 versus 66.7 %). Conclusion. The analysis of TYMS gene copy number is more suitable than TYMS protein expression for assessment of TYMS expression. TYMS gene amplification predicts outcome of patients receiving PMT with advanced NSCLC (AU)
RESUMEN
No disponible
Subject(s)
Search on Google
Collection: National databases / Spain Database: IBECS Main subject: Thymidylate Synthase / Chemotherapy, Adjuvant / Carcinoma, Non-Small-Cell Lung / Japan Type of study: Diagnostic study / Evaluation study / Observational study / Prognostic study / Risk factors Limits: Female / Humans / Male Country/Region as subject: Asia Language: English Journal: Clin. transl. oncol. (Print) Year: 2016 Document type: Article Institution/Affiliation country: Nihon University School of Medicine/Japan
Search on Google
Collection: National databases / Spain Database: IBECS Main subject: Thymidylate Synthase / Chemotherapy, Adjuvant / Carcinoma, Non-Small-Cell Lung / Japan Type of study: Diagnostic study / Evaluation study / Observational study / Prognostic study / Risk factors Limits: Female / Humans / Male Country/Region as subject: Asia Language: English Journal: Clin. transl. oncol. (Print) Year: 2016 Document type: Article Institution/Affiliation country: Nihon University School of Medicine/Japan
...